# Pancreatic Enzyme Supplementation for Celiac Disease

> **NCT02475369** · PHASE4 · TERMINATED · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 21 (actual)

## Conditions studied

- Celiac Disease

## Interventions

- **DRUG:** pancrelipase

## Key facts

- **NCT ID:** NCT02475369
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-05
- **Primary completion:** 2019-06
- **Final completion:** 2019-12
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** The trial was terminated prematurely by the sponsor for administrative reasons.
- **Last updated:** 2021-05-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02475369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02475369, "Pancreatic Enzyme Supplementation for Celiac Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02475369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*